content: UNITED STATES
  
                         SECURITIES AND EXCHANGE COMMISSION
  
                               WASHINGTON, D.C. 20549
  
                        -------------------------------------
  
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                       PURSUANT TO SECTION 13 OR 15(d) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
        Date of report (Date of earliest event reported): September 27, 2004
                                                          ------------------
  
                                 CYTOGEN CORPORATION
             -----------------------------------------------------------
                 (Exact Name of Registrant as Specified in Charter)
  
  
          Delaware                      000-14879                  22-2322400
  ----------------------------   ------------------------     --------------------
  (State or Other Jurisdiction   (Commission File Number)       (I.R.S. Employer
       of Incorporation)                                       Identification No.)
  
    650 College Road East, CN 5308, Suite 3100, Princeton, NJ           08540
  -----------------------------------------------------------       --------------
           (Address of Principal Executive Offices)                   (Zip Code)
  
         Registrant's telephone number, including area code: (609) 750-8200
                                                             --------------
  
  --------------------------------------------------------------------------------
            (Former Name or Former Address, if Changed Since Last Report)
  
       Check the  appropriate  box below if the Form 8-K  filing  is  intended  to
  simultaneously  satisfy the filing obligation of the registrant under any of the
  following provisions (see General Instruction A.2. below):
  
       |_| Written  communications  pursuant to Rule 425 under the  Securities Act
  (17 CFR 230.425)
  
       |_| Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17
  CFR 240.14a-12)
  
       |_| Pre-commencement  communications  pursuant to  Rule 14d-2(b)  under the
  Exchange Act (17 CFR 240.14d-2(b))
  
       |_| Pre-commencement  communications  pursuant to  Rule 13e-4(c)  under the
  Exchange Act (17 CFR 240.13e-4(c))
  
  <PAGE>
  
  
  ITEM 8.01   OTHER EVENTS.
  
       On September  29,  2004,  Cytogen  Corporation  (the  "Company")  announced
  settlement of a patent  infringement suit against the Company and C.R. Bard Inc.
  ("Bard")  for  an  undisclosed  payment,  without  any  admission  of  fault  or
  liability.  Immunomedics,  Inc. ("Immunomedics") filed suit on February 17, 2000
  against the Company and Bard, alleging that use of the Company's  ProstaScint(R)
  product infringed U.S. Patent No. 4,460,559, which claims a method for detecting
  and localizing  tumors.  The settlement  with  Immunomedics  is on behalf of the
  Company and Bard.
  
       The full text of the September 29, 2004 press release  issued in connection
  with the announcement is attached as Exhibit 99.1 to this Current Report on Form
  8-K.
  
  ITEM 9.01   FINANCIAL STATEMENTS AND EXHIBITS
  
  (c) Exhibits.
  
          Exhibit No.       Description
          -----------       -----------
             99.1           Press Release of the Company dated September 29, 2004
  
  
  
  <PAGE>
  
  
                                     SIGNATURES
  
  
       Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
  Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
  undersigned hereunto duly authorized.
  
                                               CYTOGEN CORPORATION
  
  
  
                                               By:   /s/ Michael D. Becker
                                                     -----------------------------
                                                     Michael D. Becker
                                                     President and Chief Executive
                                                     Officer
  
  Dated:   September 29, 2004
  
  
  
  <PAGE>
  
  
                                    EXHIBIT INDEX
  
  
            Exhibit No.      Description
            -----------      -----------
                99.1         Press Release of the Company dated September 29, 2004
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "form8k_092804.txt", "description": "FORM 8-K - IMMUNOMEDICS 09/28/04", "secsgml_size_bytes": 4203}]
metadata_filer: {"company-data": {"conformed-name": "CYTOGEN CORP", "cik": "0000725058", "assigned-sic": "2834", "irs-number": "222322400", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-14879", "film-number": "041051606"}, "business-address": {"street1": "650 COLLEGE RD EAST STE 3100", "city": "PRINCETON", "state": "NJ", "zip": "08540", "phone": "6099878200"}, "mail-address": {"street1": "650 COLLEGE RD EAST STE 3100", "city": "PRINCETON", "state": "NJ", "zip": "08540"}}
text: UNITED STATES
  
                         SECURITIES AND EXCHANGE COMMISSION
  
                               WASHINGTON, D.C. 20549
  
                        -------------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                       PURSUANT TO SECTION 13 OR 15(d) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
        Date of report (Date of earliest event reported): September 27, 2004
                                                          ------------------
  
                                 CYTOGEN CORPORATION
             -----------------------------------------------------------
                 (Exact Name of Registrant as Specified in Charter)
  
          Delaware                      000-14879                  22-2322400
  ----------------------------   ------------------------     --------------------
  (State or Other Jurisdiction   (Commission File Number)       (I.R.S. Employer
       of Incorporation)                                       Identification No.)
  
    650 College Road East, CN 5308, Suite 3100, Princeton, NJ           08540
  -----------------------------------------------------------       --------------
           (Address of Principal Executive Offices)                   (Zip Code)
  
         Registrant's telephone number, including area code: (609) 750-8200
                                                             --------------
  
  --------------------------------------------------------------------------------
            (Former Name or Former Address, if Changed Since Last Report)
  
       Check the  appropriate  box below if the Form 8-K  filing  is  intended  to
  simultaneously  satisfy the filing obligation of the registrant under any of the
  following provisions (see General Instruction A.2. below):
  
       |_| Written  communications  pursuant to Rule 425 under the  Securities Act
  (17 CFR 230.425)
  
       |_| Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17
  CFR 240.14a-12)
  
       |_| Pre-commencement  communications  pursuant to  Rule 14d-2(b)  under the
  Exchange Act (17 CFR 240.14d-2(b))
  
       |_| Pre-commencement  communications  pursuant to  Rule 13e-4(c)  under the
  Exchange Act (17 CFR 240.13e-4(c))
  ITEM 8.01   OTHER EVENTS.
  
       On September  29,  2004,  Cytogen  Corporation  (the  "Company")  announced
  settlement of a patent  infringement suit against the Company and C.R. Bard Inc.
  ("Bard")  for  an  undisclosed  payment,  without  any  admission  of  fault  or
  liability.  Immunomedics,  Inc. ("Immunomedics") filed suit on February 17, 2000
  against the Company and Bard, alleging that use of the Company's  ProstaScint(R)
  product infringed U.S. Patent No. 4,460,559, which claims a method for detecting
  and localizing  tumors.  The settlement  with  Immunomedics  is on behalf of the
  Company and Bard.
  
       The full text of the September 29, 2004 press release  issued in connection
  with the announcement is attached as Exhibit 99.1 to this Current Report on Form
  8-K.
  
  ITEM 9.01   FINANCIAL STATEMENTS AND EXHIBITS
  
  (c) Exhibits.
  
          Exhibit No.       Description
          -----------       -----------
             99.1           Press Release of the Company dated September 29, 2004
  SIGNATURES
  
       Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
  Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
  undersigned hereunto duly authorized.
  
                                               CYTOGEN CORPORATION
  
                                               By:   /s/ Michael D. Becker
                                                     -----------------------------
                                                     Michael D. Becker
                                                     President and Chief Executive
                                                     Officer
  
  Dated:   September 29, 2004
  EXHIBIT INDEX
  
            Exhibit No.      Description
            -----------      -----------
                99.1         Press Release of the Company dated September 29, 2004